Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A2

Journal of Lipid Research

Volumn 51, Issue 4, 2010, Pages 743-754

  Annema, Wijtske ^a,c   Nijstad, Niels ^a   Tölle, Markus ^d   De Boer, Jan Freark ^a   Buijs, Ruben V C ^a   Heeringa, Peter ^b   Der Giet, Markus Van ^b   Tietge, Uwe J F ^a,b  

^a Center for Liver Digestive and Metabolic Diseases   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atherosclerosis; Feces; Infl ammation; Mice; Sepsis

Indexed keywords

ACUTE PHASE PROTEIN; BILE ACID; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; SECRETORY PHOSPHOLIPASE A2; SERUM AMYLOID A; STEROL; TRITIUM; LIPID; LIPOPROTEIN; MESSENGER RNA; PEROXIDASE; PHOSPHOLIPASE A2 GROUP II; STEROID;

ACUTE PHASE RESPONSE; ADENOVIRUS; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BILE ACID SYNTHESIS; CELL LABELING; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DEFECATION; FEMALE; FOAM CELL; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; CHEMISTRY; ENZYMOLOGY; FECES; GENETICS; ISOLATION AND PURIFICATION; LIVER; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEPSIS; TRANSPORT AT THE CELLULAR LEVEL;

ACUTE-PHASE REACTION; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHOLESTEROL; FECES; FOAM CELLS; GROUP II PHOSPHOLIPASES A2; HUMANS; LIPIDS; LIPOPROTEINS; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; PEROXIDASE; RNA, MESSENGER; SEPSIS; SERUM AMYLOID A PROTEIN; STEROIDS;

EID: 77950604454     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M000323     Document Type: Article

References (59)

1. Assmann, G., and A. M. Gotto, Jr. 2004. HDL cholesterol and pro-tective factors in atherosclerosis. Circulation. 109: III8-III14.
2. Linsel-Nitschke, P., and A. R. Tall. 2005. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4: 193-205.
3. Rader, D. J., E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat. 2009. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50 (Suppl): S189-S194.
4. Libby, P. 2002. Infl ammation in atherosclerosis. Nature. 420: 868-874.
5. Ross, R. 1999. Atherosclerosis-an infl ammatory disease. N. Engl. J. Med. 340: 115-126.
6. Rader, D. J., and A. Daugherty. 2008. Translating molecular discov-eries into new therapies for atherosclerosis. Nature. 451: 904-913.
7. Steinberg, D. 2002. Atherogenesis in perspective: hypercholes-terolemia and infl ammation as partners in crime. Nat. Med. 8: 1211-1217.
8. Tsimikas, S., J. T. Willerson, and P. M. Ridker. 2006. C-reactive pro-tein and other emerging blood biomarkers to optimize risk stratifi-cation of vulnerable patients. J. Am. Coll. Cardiol. 47: C19-C31.
9. Rader, D. J. 2000. Infl ammatory markers of coronary risk. N. Engl. J. Med. 343: 1179-1182.
10. Luchtefeld, M., H. Schunkert, M. Stoll, T. Selle, R. Lorier, K. Grote, C. Sagebiel, K. Jagavelu, U. J. F. Tietge, U. Assmus, et al. 2007. Signal transducer of infl ammation gp130 modulates atherosclerosis in mice and man. J. Exp. Med. 204: 1935-1944.
11. Tietge, U. J. F., C. Maugeais, W. Cain, and D. J. Rader. 2003. Acute infl ammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. Am. J. Physiol. Endocrinol. Metab. 285: E403-E411.
12. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and infl ammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196.
13. van der Westhuyzen, D. R., F. C. de Beer, and N. R. Webb. 2007. HDL cholesterol transport during infl ammation. Curr. Opin. Lipidol. 18: 147-151
14. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: defi nitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. 1992. Crit. Care Med. 20: 864-874.
15. Tietge, U. J. F., C. Maugeais, W. Cain, D. Grass, J. M. Glick, F. C. de Beer, and D. J. Rader. 2000. Overexpression of secretory phos-pholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J. Biol. Chem. 275: 10077-10084.
16. Wiersma, H., A. Gatti, N. Nijstad, F. Kuipers, and U. J. F. Tietge. 2009. Hepatic SR-BI but not endothelial lipase expression determines biliary cholesterol secretion in mice. J. Lipid Res. 50: 1571-1580.
17. Tietge, U. J. F., K. F. Kozarsky, M. H. Donahee, and D. J. Rader. 2003. A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver. J. Gene Med. 5: 567-575.
18. Tietge, U. J. F., D. Pratico, T. Ding, C. D. Funk, R. B. Hildebrand, T. Van Berkel, and M. Van Eck. 2005. Macrophage-specifi c expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J. Lipid Res. 46: 1604-1614.
19. Heeringa, P., P. Foucher, P. A. Klok, M. G. Huitema, J. W. Tervaert, J. J. Weening, and C. G. Kallenberg. 1997. Systemic injection of products of activated neutrophils and H2O2 in myeloperoxidase-immunized rats leads to necrotizing vasculitis in the lungs and gut. Am. J. Pathol. 151: 131-140.
20. Nijstad, N., H. Wiersma, T. Gautier, M. van der Giet, C. Maugeais, and U. J. F. Tietge. 2009. Scavenger receptor BI-mediated selective uptake is required for the remodeling of high density lipoprotein by endothelial lipase. J. Biol. Chem. 284: 6093-6100.
21. Tietge, U. J. F., N. Nijstad, R. Havinga, J. F. Baller, F. H. van der Sluijs, V. W. Bloks, T. Gautier, and F. Kuipers. 2008. Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion. J. Lipid Res. 49: 563-571.
22. Heeringa, P., E. Brouwer, P. A. Klok, M. G. Huitema, J. van den Born, J. J. Weening, and C. G. Kallenberg. 1996. Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. Am. J. Pathol. 149: 1695-1706. (Pubitemid 26363975)
23. Zhang, Y., I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D.J. Rader. 2003. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 108: 661-663.
24. Hosoai, H., N. R. Webb, J. M. Glick, U. J. F. Tietge, M. S. Purdom, F. C. de Beer, and D. J. Rader. 1999. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J. Lipid Res. 40: 648-653.
25. McGillicuddy, F. C., M. de la Llera Moya, C. C. Hinkle, M. R. Joshi, E.H. Chiquoine, J. T. Billheimer, G. H. Rothblat, and M. P. Reilly. 2009. Infl ammation impairs reverse cholesterol transport in vivo. Circulation. 119: 1135-1145.
26. Tietge, U. J. F., C. Maugeais, S. Lund-Katz, D. Grass, F. C. deBeer, and D. J. Rader. 2002. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to infl ammation in human apoA-I transgenic mice. Arterioscler. Thromb. Vasc. Biol. 22: 1213-1218.
27. de Beer, F. C., P. M. Connell, J. Yu, M. C. de Beer, N. R. Webb, and D. R. van der Westhuyzen. 2000. HDL modifi cation by secretory phospholipase A(2) promotes scavenger receptor class B type I interaction and accelerates HDL catabolism. J. Lipid Res. 41: 1849-1857.
28. Zheng, L., B. Nukuna, M. L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P. L. Fox, et al. 2004. Apolipoprotein A-I is a selective target for myeloperoxidase-cata-lyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114: 529-541.
29. Shao, B., M. N. Oda, C. Bergt, X. Fu, P. S. Green, N. Brot, J. F. Oram, and J. W. Heinecke. 2006. Myeloperoxidase impairs ABCA1-dependent cholesterol effl ux through methionine oxidation and site-specifi c tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem. 281: 9001-9004.
30. Noguchi, N., K. Nakano, Y. Aratani, H. Koyama, T. Kodama, and E. Niki. 2000. Role of myeloperoxidase in the neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidase-knockout mouse. J. Biochem. 127: 971-976.
31. Rausch, P. G., and T. G. Moore. 1975. Granule enzymes of poly-morphonuclear neutrophils: a phylogenetic comparison. Blood. 46: 913-919.
32. Marsche, G., A. Hammer, O. Oskolkova, K. F. Kozarsky, W. Sattler, and E. Malle. 2002. Hypochlorite-modifi ed high density lipoprotein, a high affi nity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J. Biol. Chem. 277: 32172-32179.
33. Haque, S., H. Mirjafari, and I. N. Bruce. 2008. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr. Opin. Lipidol. 19: 338-343.
34. Cai, L., A. Ji, F. C. de Beer, L. R. Tannock, and D. R. van der Westhuyzen. 2008. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J. Clin. Invest. 118: 364-375.
35. Connelly, M. A. 2009. SR-BI-mediated HDL cholesteryl ester deliv-ery in the adrenal gland. Mol. Cell. Endocrinol. 300: 83-88.
36. Baranova, I., T. Vishnyakova, A. Bocharov, Z. Chen, A. T. Remaley, J. Stonik, T. L. Eggerman, and A. P. Patterson. 2002. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect. Immun. 70: 2995-3003.
37. Khovidhunkit, W., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2003. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J. Lipid Res. 44: 1728-1736.
38. Artl, A., G. Marsche, S. Lestavel, W. Sattler, and E. Malle. 2000. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol. 20: 763-772.
39. Khovidhunkit, W., J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2001. Cholesterol effl ux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. J. Lipid Res. 42: 967-975.
40. Pussinen, P. J., M. Jauhiainen, T. Vilkuna-Rautiainen, J. Sundvall, M. Vesanen, K. Mattila, T. Palosuo, G. Alfthan, and S. Asikainen. 2004. Periodontitis decreases the antiatherogenic potency of high density lipoprotein. J. Lipid Res. 45: 139-147.
41. Jahangiri, A., M. C. de Beer, V. Noffsinger, L. R. Tannock, C. Ramaiah, N. R. Webb, D. R. van der Westhuyzen, and F. C. de Beer. 2009. HDL remodeling during the acute phase response. Arterioscler. Thromb. Vasc. Biol. 29: 261-267.
42. Cabana, V. G., C. A. Reardon, B. Wei, J. R. Lukens, and G. S. Getz. 1999. SAA-only HDL formed during the acute phase response in apoA-I+/+ and apoA-I\/\ mice. J. Lipid Res. 40: 1090-1103.
43. Coetzee, G. A., A. F. Strachan, D. R. van der Westhuyzen, H. C. Hoppe, M. S. Jeenah, and F. C. de Beer. 1986. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261: 9644-9651.
44. Stonik, J. A., A. T. Remaley, S. J. Demosky, E. B. Neufeld, A Bocharov, and H. B. Brewer. 2004. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid effl ux from cells. Biochem. Biophys. Res. Commun. 321: 936-941.
45. van der Westhuyzen, D. R., L. Cai, M. C. de Beer, and F. C. de Beer. 2005. Serum amyloid A promotes cholesterol effl ux mediated by scavenger receptor B-I. J. Biol. Chem. 280: 35890-35895.
46. Banka, C. L., T. Yuan, M. C. de Beer, M. Kindy, L. K. Curtiss, and F. C. de Beer. 1995. Serum amyloid A (SAA): infl uence on HDL-mediated cellular cholesterol effl ux. J. Lipid Res. 36: 1058-1065.
47. Cai, L., M. C. de Beer, F. C. de Beer, and D. R. van der Westhuyzen. 2005. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J. Biol. Chem. 280: 2954-2961.
48. Ivandic, B., L. W. Castellani, X. P. Wang, J. H. Qiao, M. Mehrabian, M. Navab, A. M. Fogelman, D. S. Grass, M. E. Swanson, M. C. de Beer, et al. 1999. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 19: 1284-1290.
49. Boekholdt, S. M., T. T. Keller, N. J. Wareham, R. Luben, S. A Bingham, N. E. Day, M. S. Sandhu, J. W. Jukema, J. J. Kastelein, C. E. Hack, et al. 2005. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler. Thromb. Vasc. Biol. 25: 839-846.
50. Kugiyama, K., Y. Ota, K. Takazoe, Y Moriyama, H. Kawano, Y Miyao, T. Sakamoto, H. Soejima, H. Ogawa, H. Doi, et al. 1999. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 100: 1280-1284. (Pubitemid 29440119)
51. Mallat, Z., P. G. Steg, J. Benessiano, M. L. Tanguy, K. A. Fox, J. P. Collet, O. H. Dabbous, P. Henry, K. F. Carruthers, A. Dauphin, et al. 2005. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J. Am. Coll. Cardiol. 46: 1249-1257.
52. Vaisar, T., B. Shao, P. S. Green, M. N. Oda, J. F. Oram, and J. W. Heinecke. 2007. Myeloperoxidase and infl ammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans. Curr. Atheroscler. Rep. 9: 417-424.
53. Nicholls, S. J., and S. L. Hazen. 2009. Myeloperoxidase, modifi ed li-poproteins, and atherogenesis. J. Lipid Res. 50 (Suppl): S346-S351.
54. Shao, B., G. Cavigiolio, N. Brot, M. N. Oda, and J. W. Heinecke. 2008. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 105: 12224-12229.
55. Zhang, R., M. L. Brennan, X. Fu, R. J. Aviles, G. L. Pearce, M. S. Penn, E. J. Topol, D. L. Sprecher, and S. L. Hazen. 2001. Association between myeloperoxidase levels and risk of coronary artery disease. J. Am. Med. Assoc. 286: 2136-2142.
56. Masucci-Magoulas, L., P. Moulin, X. C. Jiang, H. Richardson, A. Walsh, J. L. Breslow, and A. Tall. 1995. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J. Clin. Invest. 95: 1587-1594.
57. Hardardóttir, I., A. H. Moser, J. Fuller, C. Fielding, K. Feingold, and C. Grunfeld. 1996. Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in syrian hamsters. J. Clin. Invest. 97: 2585-2592. (Pubitemid 26187346)
58. Feingold, K. R., D. K. Spady, A. S. Pollock, A. H. Moser, and C. Grunfeld. 1996. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J. Lipid Res. 37: 223-228.
59. Memon, R. A., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2001. In vivo and in vitro regulation of sterol 27-hydroxy-lase in the liver during the acute phase response. potential role of hepatocyte nuclear factor-1. J. Biol. Chem. 276: 30118-30126.